Traders should monitor the AACR presentation for additional clinical details and watch for updates on Immatics' planned pediatric development program, which could expand the addressable market for its PRAME-directed therapies and support future trial designs or partnerships.
IMTX drugs
IMTX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 17 $11.17entry
- T+1 · 7mo ago +0.72%α +0.91% · $11.25
- T+5 · 7mo ago +1.61%α +1.06% · $11.35
- T+20 · 6mo ago 0.00%α −5.37% · $11.17
- T+60 · 4mo ago −16.29%α −22.44% · $9.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immatics announced a deep and ongoing remission in a 17-year-old pediatric patient with advanced nephroblastoma after treatment with its PRAME-directed TCR T-cell therapy (IMA203CD8) under a named-patient use program. The case, to be presented at AACR 2026, demonstrates strong anti-tumor activity across multiple metastatic sites and supports the potential of PRAME-targeted cell therapy in pediatric solid tumors.
Key Facts
- 17-year-old pediatric patient with PRAME-positive nephroblastoma achieved deep remission after treatment with Immatics' IMA203CD8 TCR T-cell therapy.
- Remission included marked regression of liver, lung, and brain metastases, ongoing at 6 months post-infusion.
- Molecular remission confirmed via liquid biopsy with no detectable tumor-derived DNA.
- Safety events included manageable cytokine release syndrome resolved with standard therapy.
- Data to be presented in a late-breaking poster at AACR Annual Meeting 2026.
- Immatics plans a potential Phase 1/2 basket study in pediatric patients with PRAME-positive solid tumors.
Financial Impact
No direct financial impact disclosed, but significant strategic and clinical validation for Immatics' PRAME platform.
Risk Factors
- Single-patient case study with no control group; results may not be reproducible.
- Named-patient use is not a controlled clinical trial; regulatory path remains uncertain.
- Forward-looking statements about future trials and commercial potential are subject to development risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276451 |
Track record
23 reports on IMTX
7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 8 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 5/10 No price data
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
- Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
- Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
- Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers